Clinical pharmacology of phenelzine.

There is renewed interest in the clinical pharmacology of phenelzine sulfate and other monoamine oxidase (MAO) inhibitors. Newer clinical and analytic techniques recently have been applied to investigations of this class of drugs in man. The results show that drugs such as phenelzine are effective in nonendogenous depression and phobic disorders. Clinical response to phenelzine is related to platelet MAO inhibition and dosage per unit body weight. High percent MAO inhibition in platelets at two weeks is associated with greater improvement after a six-week course of treatment. Our data show that a safe, effective phenelzine dose in 1 mg/kg body weight per day. These results have delineated the pharmacologic and therapeutic effects of phenelzine and support a continuing role for MAO inhibitors in psychopharmacology.

[1]  J. Davidson,et al.  Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression. , 1978, The American journal of psychiatry.

[2]  E. Johnstone.  The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine , 1976, Psychopharmacologia.

[3]  K. Lamborn,et al.  A multiple-dose, controlled study of phenelzine in depression-anxiety states. , 1976, Archives of general psychiatry.

[4]  A. Dimascio,et al.  RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE , 1975, The Journal of nervous and mental disease.

[5]  T. Crook,et al.  Depression subtypes and response to phenelzine, diazepam, and a placebo. Results of a nine hospital collaborative study. , 1974, Archives of general psychiatry.

[6]  K. Lamborn,et al.  The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial. , 1973, Archives of general psychiatry.

[7]  T. Fahy,et al.  A Double-Blind Trial of Phenelzine and Amitriptyline in Depressed Out-Patients. a Possible Differential Effect of the Drugs on Symptoms , 1973, British Journal of Psychiatry.

[8]  E. Johnstone,et al.  Acetylator status and response to phenelzine in depressed patients. , 1973, Lancet.

[9]  I. Oswald,et al.  Phenelzine, mood response, and sleep. , 1973, Archives of general psychiatry.

[10]  P. Tyrer,et al.  Phenelzine in phobic anxiety: a controlled trial , 1973, Psychological Medicine.

[11]  E. Paykel,et al.  Depressive Typologies and Response to Amitriptyline , 1972, British Journal of Psychiatry.

[12]  E. Paykel,et al.  Classification of Depressed Patients: A Cluster Analysis Derived Grouping , 1971, British Journal of Psychiatry.

[13]  R. Kendell.  The Classification of Depressive Illnesses , 1970, British Journal of Psychiatry.

[14]  J. Mendels,et al.  The nosology of depression: the endogenous-reactive concept. , 1968, The American journal of psychiatry.

[15]  W. Lovenberg,et al.  Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. , 1968, Biochemical pharmacology.

[16]  J. Gudeman,et al.  The endogenous depressive pattern. An empirical investigation. , 1967, Archives of general psychiatry.

[17]  M. Roth,et al.  The Diagnosis of Depressive Syndromes and the Prediction of E.C.T. Response , 1965, British Journal of Psychiatry.

[18]  D. Price Evans,et al.  The influence of acetylator phenotype on the effects of treating depression with phenelzine , 1965, Clinical pharmacology and therapeutics.

[19]  Schiele Bc.  THE PARNATE-SPECIFIC PATIENT. , 1965 .

[20]  L. Kiloh,et al.  The Independence of Neurotic Depression and Endogenous Depression , 1963, British Journal of Psychiatry.

[21]  J. Dominian,et al.  Phenelzine and Dexamphetamine in Depressive Illness , 1962 .

[22]  P. Dally,et al.  Treatment of Anxiety States by Antidepressant Drugs , 1962, British medical journal.

[23]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[24]  T. J. Bates,et al.  A comparative trial of four monoamine oxidase inhibitors on chronic depressives. , 1961, The Journal of mental science.

[25]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[26]  L. Rees,et al.  An evaluation of iproniazid (marsilid) in the treatment of depression. , 1960, The Journal of mental science.

[27]  M. Hamilton,et al.  Clinical syndromes in depressive states. , 1959, The Journal of mental science.

[28]  P. Dally,et al.  Effects of Iproniazid in Depressive Syndromes , 1959, British medical journal.

[29]  Davis Wa.  The history of marsilid. , 1958 .

[30]  Bosworth Dm.  Discussion of the history of marsilid. , 1958 .

[31]  N. Kline,et al.  A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. , 1957, Psychiatric research reports.